Hanna Jean Khoury

Summary

Affiliation: Emory University
Country: USA

Publications

  1. doi request reprint A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias
    Hanna Jean Khoury
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA
    Cancer 118:3556-64. 2012
  2. doi request reprint Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis
    H J Khoury
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Bone Marrow Transplant 47:810-6. 2012
  3. doi request reprint Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
    H Jean Khoury
    Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
    Blood 119:3403-12. 2012
  4. pmc Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation
    Hanna J Khoury
    Center for International Blood and Marrow Transplant Research CIBMTR, Health Policy Institute, Medical College of Wisconsin, Milwaukee, USA
    Blood 107:1712-6. 2006
  5. doi request reprint Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations
    Hanna Jean Khoury
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Cancer 115:1381-94. 2009
  6. doi request reprint Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?
    Lisa M Lima
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Leuk Lymphoma 52:1010-6. 2011
  7. doi request reprint Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond
    Lisa Lima
    Department of Hematology and Medial Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia 30322, USA
    Cancer 117:1245-52. 2011
  8. doi request reprint Tools to optimize the functionality of a leukemia clinical trial team
    Beverly Bethelmie-Bryan
    Clinical Trials Office of Winship Cancer Institute of Emory University, Atlanta, GA, USA
    Leuk Lymphoma 54:110-6. 2013
  9. doi request reprint A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas
    Rajni Sinha
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Cancer 118:3538-48. 2012
  10. doi request reprint Bosutinib treatment for Philadelphia chromosome-positive leukemias
    Beverly Bethelmie-Bryan
    Division of Hematology, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, 1365 Clifton Road, Atlanta, GA 30322, USA
    Future Oncol 10:179-85. 2014

Collaborators

Detail Information

Publications15

  1. doi request reprint A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias
    Hanna Jean Khoury
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA
    Cancer 118:3556-64. 2012
    ..ARRY-520 selectively inhibits the mitotic kinesin spindle protein (KSP), which leads to abnormal monopolar spindle formation and apoptosis...
  2. doi request reprint Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis
    H J Khoury
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Bone Marrow Transplant 47:810-6. 2012
    ..In conclusion, there are no new prognostic indicators of the outcomes of allogeneic hematopoietic SCT for advanced-phase CML in the IM era...
  3. doi request reprint Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
    H Jean Khoury
    Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
    Blood 119:3403-12. 2012
    ..Bosutinib may offer a new treatment option for patients with chronic-phase CML after treatment with multiple TKIs. This trial was registered at www.clinicaltrials.gov as NCT00261846...
  4. pmc Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation
    Hanna J Khoury
    Center for International Blood and Marrow Transplant Research CIBMTR, Health Policy Institute, Medical College of Wisconsin, Milwaukee, USA
    Blood 107:1712-6. 2006
    ..In conclusion, results of this study found no long-term benefit or disadvantage of giving G-CSF after transplantation to promote hematopoietic recovery...
  5. doi request reprint Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations
    Hanna Jean Khoury
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Cancer 115:1381-94. 2009
    ..On the basis of more than 2 years' experience of dasatinib treatment during clinical trials, they provide practical recommendations for side-effect management...
  6. doi request reprint Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?
    Lisa M Lima
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Leuk Lymphoma 52:1010-6. 2011
    ..In conclusion, IM-associated cytopenias are associated with a high pre-IM FISH, are reversible, and do not adversely affect outcomes...
  7. doi request reprint Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond
    Lisa Lima
    Department of Hematology and Medial Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia 30322, USA
    Cancer 117:1245-52. 2011
    ....
  8. doi request reprint Tools to optimize the functionality of a leukemia clinical trial team
    Beverly Bethelmie-Bryan
    Clinical Trials Office of Winship Cancer Institute of Emory University, Atlanta, GA, USA
    Leuk Lymphoma 54:110-6. 2013
    ..We conclude that technology combined with a coordinated team care approach can facilitate the integration of trials in clinical practice...
  9. doi request reprint A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas
    Rajni Sinha
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Cancer 118:3538-48. 2012
    ..A phase 1 study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone (R-CHOP) was conducted in patients with untreated follicular lymphoma (FL) and other indolent NHLs...
  10. doi request reprint Bosutinib treatment for Philadelphia chromosome-positive leukemias
    Beverly Bethelmie-Bryan
    Division of Hematology, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, 1365 Clifton Road, Atlanta, GA 30322, USA
    Future Oncol 10:179-85. 2014
    ..This article summarizes the pharmacokinetics, pharmacodynamics, safety and efficacy of bosutinib for the treatment of Philadelphia chromosome-positive leukemias. ..
  11. pmc Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?
    John T Horan
    Children s Healthcare of Atlanta at Egleston, Emory University Hospital, Atlanta, GA, USA
    J Clin Oncol 29:805-13. 2011
    ..Transplantation-related mortality (TRM) is a major barrier to the success of allogeneic hematopoietic cell transplantation (HCT)...
  12. ncbi request reprint Advances in hematopoietic stem cell transplantation in chronic myeloid leukemia
    Rachel Veldman
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    Discov Med 16:179-86. 2013
    ....
  13. doi request reprint Managing chronic myeloid leukemia: a coordinated team care perspective
    Stacie Holloway
    Emory Healthcare, Atlanta, GA, USA
    Clin Lymphoma Myeloma Leuk 12:88-93. 2012
    ..This approach provided patients with education and a good understanding of response to therapy and improved relations with the health care team...
  14. pmc The Smac mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac
    Sampath Ramachandiran
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Leuk Res 36:784-90. 2012
    ..Furthermore, we identified that RMT promotes caspase 3 and 9 cleavage by inhibiting XIAP and inducing the mitochondrial efflux of Smac and cytochrome C. This investigation further support exploring the use of Smac inhibitors in VAL...
  15. pmc Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
    Lisa M Lima
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
    J Blood Med 1:221-5. 2010
    ..Safety and tolerability as well as practical tips for management of side-effects, and drug interactions are included...